Karyopharm Therapeutics (KPTI) EPS (Basic) Growth (5y) (2017 - 2026)
Powered by 
Analysis
Karyopharm Therapeutics (KPTI) EPS (Basic) Growth (5y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.98 Bn | 621.22 Bn | 17.26 Bn |
| 2 | AbbVie | 446.60 Bn | 440.03 Bn | 12.70 Bn |
| 3 | Merck | 357.75 Bn | 350.61 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.43 Bn | 259.74 Bn | 11.24 Bn |
| 5 | Pfizer | 156.61 Bn | 144.91 Bn | 10.94 Bn |
| 6 | Sanofi | 52.22 Bn | 44.84 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.95 Bn | 42.95 Bn | - |
| 8 | Incyte | 24.57 Bn | 20.04 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.31 Bn | 18.65 Bn | 683.80 Mn |
| 10 | Karyopharm Therapeutics | 46.30 Mn | -18.80 Mn | 32.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.35% |
| Dec 31, 2025 | 9.20% |
| Sep 30, 2025 | 18.94% |
| Jun 30, 2025 | 14.59% |
| Mar 31, 2025 | 26.39% |
| Dec 31, 2024 | 20.25% |
| Sep 30, 2024 | 17.37% |
| Jun 30, 2024 | 17.88% |
| Mar 31, 2024 | 21.52% |
| Dec 31, 2023 | 18.50% |
| Sep 30, 2023 | 17.59% |
| Jun 30, 2023 | 13.79% |
| Mar 31, 2023 | 17.26% |
| Dec 31, 2022 | 10.75% |
| Sep 30, 2022 | 6.97% |
| Jun 30, 2022 | 0.80% |
| Mar 31, 2022 | 5.66% |
| Dec 31, 2021 | 22.16% |
| Sep 30, 2021 | 0.11% |
| Jun 30, 2021 | 3.21% |